Table 7.
Relative effect sizes for risk of treatment discontinuation due to adverse events
| Regimen | Risk of treatment discontinuation due to AEs | |||
|---|---|---|---|---|
| Fixed effect model | Random effects model | |||
| All vs. placebo | Exenatide QW vs. all | All vs. placebo | Exenatide QW vs. all | |
| Odds ratio (95% CrI) | Odds ratio (95% CrI) | Odds ratio (95% CrI) | Odds ratio (95% CrI) | |
| Placebo | N/A | 12.78 (1.82, 97.03)* | N/A | 13.01 (0.46, 342.41) |
| Exenatide 5 µg BID | 2.90 (0.64, 12.43) | 4.41 (0.48, 43.64) | 3.49 (0.36, 48.96) | 3.73 (0.07, 141.17) |
| Lixisenatide 20 µg QD | 4.45 (2.07, 10.79)* | 2.87 (0.49, 18.25) | 4.76 (1.26, 20.84)* | 2.73 (0.12, 51.16) |
| Exenatide 10 µg BID | 5.91 (2.51, 15.36)* | 2.16 (0.34, 14.60) | 6.97 (1.42, 52.20)* | 1.87 (0.05, 46.25) |
| Liraglutide 1.2 mg QD | 22.20 (3.94, 134.29)* | 0.58 (0.16, 2.21) | 23.17 (1.36, 474.85)* | 0.56 (0.04, 6.75) |
| Liraglutide 1.8 mg QD | 23.88 (3.87, 157.59)* | 0.53 (0.13, 2.34) | 24.68 (1.02, 675.87)* | 0.53 (0.03, 8.42) |
| Dulaglutide 1.5 mg QW | 23.95 (3.41, 178.57)* | 0.53 (0.11, 2.69) | 24.95 (0.63, 1187.97) | 0.52 (0.01, 15.53) |
| Exenatide 2 mg QW | 12.78 (1.82, 97.03)* | N/A | 13.01 (0.46, 342.41) | N/A |
AE adverse event, BID twice daily, CrI credible interval, N/A not applicable, QD once daily, QW once weekly
* Statistically significant difference